- Home
- VINP vs SVRA Comparison
VINP vs SVRA Comparison
Compare VINP & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VINP
- SVRA
- Stock Information
- Founded
- VINP 2009
- SVRA 2007
- Country
- VINP Brazil
- SVRA United States
- Employees
- VINP N/A
- SVRA N/A
- Industry
- VINP Investment Managers
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- VINP Finance
- SVRA Health Care
- Exchange
- VINP Nasdaq
- SVRA Nasdaq
- Market Cap
- VINP 636.2M
- SVRA 527.2M
- IPO Year
- VINP 2021
- SVRA N/A
- Fundamental
- Price
- VINP $10.04
- SVRA $3.58
- Analyst Decision
- VINP Strong Buy
- SVRA Buy
- Analyst Count
- VINP 2
- SVRA 7
- Target Price
- VINP $13.50
- SVRA $6.00
- AVG Volume (30 Days)
- VINP 42.1K
- SVRA 1.6M
- Earning Date
- VINP 08-12-2025
- SVRA 08-13-2025
- Dividend Yield
- VINP 6.49%
- SVRA N/A
- EPS Growth
- VINP N/A
- SVRA N/A
- EPS
- VINP 0.50
- SVRA N/A
- Revenue
- VINP $153,475,995.00
- SVRA N/A
- Revenue This Year
- VINP $67.62
- SVRA N/A
- Revenue Next Year
- VINP $14.50
- SVRA N/A
- P/E Ratio
- VINP $19.94
- SVRA N/A
- Revenue Growth
- VINP 76.11
- SVRA N/A
- 52 Week Low
- VINP $8.66
- SVRA $1.89
- 52 Week High
- VINP $10.99
- SVRA $4.70
- Technical
- Relative Strength Index (RSI)
- VINP 54.45
- SVRA 80.01
- Support Level
- VINP $9.82
- SVRA $3.19
- Resistance Level
- VINP $10.18
- SVRA $3.28
- Average True Range (ATR)
- VINP 0.28
- SVRA 0.17
- MACD
- VINP -0.01
- SVRA 0.03
- Stochastic Oscillator
- VINP 53.73
- SVRA 92.31
About VINP Vinci Partners Investments Ltd.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.